Chunru Lin, Ph.D.
Department of Molecular Oncology, Division of Discovery Science
About Chunru Lin
I am a Professor of Molecular Oncology and Associate Director of the Cancer Center Support Grant (CCSG) Tumor Evolution and Metastasis Program at The University of Texas MD Anderson Cancer Center. My research program is dedicated to elucidating and targeting mechanisms that govern the interplay between diet, cancer metabolism, immunosuppression, and protective immunity within the tumor microenvironment (TME). We place a strong emphasis on spatial metabolomics, proteomics, and comprehensive TME mapping. By integrating translational studies using clinical specimens with mechanistic investigations in mouse models, my laboratory has uncovered key pathways linking tumor metabolism, immune evasion, and tissue-specific immunopathology.
- Over the past decade, my laboratory has elucidated critical mechanisms driving breast cancer metastasis and metabolic reprogramming. Using state-of-the-art molecular biology techniques, genome-wide analyses, and functional assays, we have characterized the signaling networks and metabolic pathways that promote tumor invasion, dissemination, and colonization at distant sites. Our work has provided foundational insights into the cellular and molecular events regulating tumor-stroma interactions, and systemic metabolic alterations in metastatic cancer (Cell 2014; Nat Cell Biol 2016; J Clin Invest 2017).
- In parallel, we have extended our research into the mechanisms of metabolic dysregulation in both inherited and metabolic disease contexts. These investigations have spanned diverse conditions including renal fibrosis (J Clin Invest 2019), muscular dystrophy (Nat Cell Biol 2020), phenylketonuria (Science 2021), and the metabolic impact of physical exercise (Genome Med 2021). These studies reflect our commitment to unraveling the molecular pathways governing metabolic homeostasis and pathological conditions, with the goal of developing novel therapeutic interventions for metabolic disorders and malignancies alike.
- A major focus of our recent work has been to understand the mechanisms of immune resistance in cancer, particularly in the setting of immunotherapy. We have defined how tumor cells evade immune surveillance through various means, including alterations in immune checkpoint signaling, modulation of antigen presentation, and the establishment of an immunosuppressive tumor microenvironment, particularly under the metabolic syndrome (Nat Immunol 2019; Sci Adv 2022; Cell Metab 2023).
- Additionally, our team has uncovered a previously underrecognized mechanism contributing to immune checkpoint inhibitor (ICI)-associated myocarditis — a severe, potentially life-threatening immune-related adverse event (irAE). Our work has begun to elucidate the molecular basis of this toxicity and identify candidate cardioprotective pathways, paving the way for precision strategies to mitigate immunotherapy-associated cardiac complications (Sci Trans Med 2022).
Present Title & Affiliation
Primary Appointment
Professor, Discovery Science, The MD Anderson UTHealth Houston Graduate School, Houston, TX
Professor, Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Professor, Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, The MD Anderson UTHealth Houston Graduate School, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | Georgia State University, Atlanta, Georgia, US, Biological Science, Ph.D |
| 1999 | Hunan Medical University, Changsha, CN, Medicine, MB |
Postgraduate Training
| 2006-2013 | Postdoctoral Fellow, Cell Biology, University of California, San Diego, San Diego, California |
Experience & Service
Faculty Academic Appointments
Associate Professor, The MD Anderson UTHealth Houston Graduate School, Houston, TX, 2019 - 2025
Associate Professor, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Assistant Professor, The MD Anderson UTHealth Houston Graduate School, Houston, TX, 2013 - 2019
Assistant Professor, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Administrative Appointments/Responsibilities
Cancer Biology Program, co-director, MD Anderson UTHealth Houston Graduate School, Houston, Texas, 2026 - Present
Associate Leader, Tumor Evolution and Metastasis Program, Cancer Center Support Grant, MD Anderson Cancer Center, The University of Texas, MD Anderson Cancer Center, 2025 - Present
Intramural Institutional Committee Activities
member, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Faculty Admissions Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Cancer Biology Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Internal advisory council of Institute for Data Science in Oncology Affiliates, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Mentoring Council, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, MCO Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Committee Member, Engagement Circles committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Women’s Leadership Network (WLN) Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Committee Member, Core Facility Oversight Board, The University of Texas MD Anderson Cancer Center, 2022 - Present
Alternate Representative of Cancer Biology Program, GSBS Academic Standards Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Committee Member, Electronic Lab Notebook (ELN) Product Demonstrations, The University of Texas MD Anderson Cancer Center, 2021 - Present
Committee Member, Functional Genomics Core (shRNA and ORFeome Core) Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Committee Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2019
Extramural Institutional Committee Activities
Committee Member, ASGCT’s Diversity & Inclusion Committee, American Society of Gene & Cell Therapy, 2024 - Present
Committee Member, Acquired Resistance to Therapy Network (ARTNet) Steering Commitee, National Institutes of Health, 2021 - Present
Editorial Activities
Editorial Board Member, Non-coding RNA, 2023 - Present
Associate Editor, RNA Biology, 2020 - Present
Scientific Editor, RNA Biology, 2019 - 2020
Honors & Awards
| 2024 | Faculty Educator of the Quarter for the second quarter of the 2024-2025 award year, MD Anderson Cancer Center |
| 2021 | Faculty Scholar Award FY2021, MD Anderson Cancer Center |
| 2021 | Excellence in Science 2021 (previously, Wall of Science), MD Anderson Cancer Center |
| 2020 | Excellence in Science 2020 (previously, Wall of Science), MD Anderson Cancer Center |
| 2020 | Sanofi-Cell Research Outstanding Research Article Award, Sanofi-Cell Research |
| 2020 | President’s Recognition of Faculty Excellence, MD Anderson Cancer Center |
| 2018 | Excellence in Science 2018 (previously, Wall of Science), MD Anderson Cancer Center |
| 2015 | Wall of Science Award for Outstanding Scientific Research, Institutional Research Executive Committee, MD Anderson |
| 2013 | Faculty Science and Technology Acquisition and Retention (STARs) Program, University of Texas |
| 2008 | Susan G. Komen Postdoctoral Fellowship Grant, Susan G Komen for the Cure |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. The Impact of Diet, Nutrition, and Metabolic Syndrome on Cancer Treatment Resistance. Invited. Center for Energy Balance Research Seminar. Houston, Texas, US.
- 2025. Genomic factors related to immunotherapy toxicities. Invited. Updates in Advanced Breast Cancer. Houston, Texas, US.
- 2024. The Dynamic Landscape of Tumor Immune Metabolism: Insights into Metabolic Disorders, and Immunotherapies. Invited. Biochemistry and Molecular Biology Seminar Series. Houston, Texas, US.
- 2024. Chromatin Introversion in Sickle Cell Disease Promotes T cell Ferroptosis. Conference. Chromatin Introversion in Sickle Cell Disease Promotes T cell Ferroptosis. Houston, TX, US.
- 2023. 2023 Minority Faculty Leadership Development Seminar. Invited. 2023 Minority Faculty Leadership Development Seminar. Houston, Texas, US.
- 2021. A noncoding RNA modulator potentiates phenylalanine metabolism. Invited. Research Town Hall. Houston, Texas, US.
- 2019. Genetic Importance of lncRNAs in Metabolic Disorders. Invited. Molecular and Cellular Biology Seminar Series. Houston, Texas, US.
- 2017. Progress, paradigms, and pathways of long noncoding RNAs in cancer. Invited. Biochemistry and Molecular Biology Seminar Series. Houston, Texas, US.
- 2016. Targeting Long non-coding RNAs in Breast Cancer. Invited. Targeting Long non-coding RNAs in Breast Cancer. Houston, TX, US.
- 2016. Lncing RNA to Cancer - Insights and Implications. Invited. Lncing RNA to Cancer - Insights and Implications. Houston, TX, US.
Regional Presentations
- 2017. Long Noncoding RNAs: Cellular Signaling Codes in Cancer. Invited. Society of Chinese Bioscientists in America. Houston, TX, US.
- 2013. Investigating the roles of long non-coding RNA in Prostate Cancer. Invited. Society of Chinese Bioscientists in America. Houston, TX, US.
National Presentations
- 2026. Phenylalanine Reprograms TLS Architecture and Plasma cell fate in MASH-HCC. Invited. International Conference on Intelligent Biology and Medicine.
- 2025. Modulating Tumor Microenvironment in Prostate Cancer Through Exercise. Invited. Inaugural Muscle Biology and Cachexia Conference. Houston, TX, US.
- 2024. Unlocking the Missing Link: Long Noncoding RNAs in Mitochondrial Biology and Cardiomyopathies. Invited. UCLA Cardiovascular Theme Symposium 2024. Los Angles, CA, US.
- 2024. Revealing the Dynamics of the NASH-HCC Tumor Microenvironment. Invited. NIH GI SPORE Monthly Meeting. On-line, US.
- 2024. ARTNet Inflammatory microenvironment and tumor cross-talk work group. Invited. Acquired Resistance to Therapy Network (ARTNet) - NCI. Houston, TX, US.
- 2023. Exploring Immune Vulnerabilities in Sickle Cell Disease: Revealing the Ferroptosis Link. Invited. Princess Margaret Joint Symposium in Cancer Metabolism. Houston, TX, US.
- 2023. Exploring the Dynamic Interplay between Immune Metabolism and Tumor Microenvironment. Invited. Acquired Resistance to Therapy Network (ARTNet) - NCI. Buffalo, NY, US.
- 2023. Targeting non-coding RNA elements to antagonize immune resistance. Invited. Acquired Resistance to Therapy Network (ARTNet) - NCI. Houston, TX, US.
- 2022. The path towards elucidating mechanisms of immune checkpoint inhibitor related cardiotoxicity. Invited. American Heart Association. Chicago, IL, US.
- 2022. Long Noncoding RNA Advocates Immune Resistant Microenvironment. Invited. The Drug Resistance and Sensitivity Network. Portland, WA, US.
- 2021. Noncoding RNA Advocates Immune Resistant Microenvironment. Invited. The Drug Resistance and Sensitivity Network. On-line, US.
International Presentations
- 2024. Unraveling the Role of lncRNA in Cardiomyopathies. Invited. RNA Collaborative Seminar Series. On-line, US.
- 2024. Unraveling Phenylalanine Metabolism: A Key Player in Immunotherapy Resistance of Non-Alcoholic Steatohepatitis-Associated Hepatocellular Carcinoma. Conference. 6th Edition of webinar on GASTROENTEROLOGY & HEPATOLOGY. On-line.
- 2024. Supporting Young Scientists in Cancer Research - The Role of Long non-coding RNAs in Tumor Microenvironment. Conference. Global Summit of Public Health. On-line, US.
- 2022. Mighty noncoding RNAs: A Key Player in Understanding Inter-disease Crosstalk. Invited. Editorial Board of Non-Coding RNA journal. On-line.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Unraveling the Molecular Mechanisms of Immunotherapy-Associated Myocarditis |
| Funding Source: | NCI |
| Role: | PI |
| ID: | 1R01CA305864-01A1 |
| Date: | 2022 - 2027 |
| Title: | Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA255080-01A1 |
Selected Publications
Peer-Reviewed Articles
- Zacharias NM, Rupe ES, Chen X, Kotecha RR, Rieke DT, McGregor BA, Pesquera P, Yu Z, Grover A, Daw NC, Wang E, Chan SWS, Douglas-Lindsay D, Fan AC, Knoche EM, Kyriakopoulos CE, Lalani AA, Mantia CM, Merla A, Voss MH, Pfanzelter N, Ramakrishna S, Reaume NM, Tang T, Ingram DR, Shamsutdinova D, Wani KM, Wang WL, Lazar AJ, Sheth RA, Rao P, Grimm SL, Coarfa C, He R, Qian J, Duan F, Bisht D, Chauhan PK, Perelli L, Genovese G, Yang L, Lin C, Karam JA, La Posta L, Dondossola E, Basar R, Uprety N, Rezvani K, Gao J, Wang L, Solis Soto LM, Lim B, Tannir NM, Karki M, Msaouel P. Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42627757.
- Lei G, Lu Z, Xu Z, Braun C, Huo D, Gao J, Tan L, Hong T, Wu S, Sun M, Zhao X, Li Q, Chen X, Yan Y, Lee H, Mao C, Zhuang L, Ku LT, Puebla N, Barsoumian H, Yao J, Hong L, Zhang J, Tran H, Lee JJ, Gibbons D, Vaporciyan A, Heymach J, Lin C, Gottlieb E, You MJ, Welsh JW, Lin SH, Zang X, Li Z, Gan B. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell 189(17):5359-5377.e11, 2026. e-Pub 2026. PMID: 42330950.
- Yu K, Chen J, Chu YY, Nair S, Crupi E, Hasanov E, Mei Y, Han X, Liu Y, Liu Y, Pei G, Peng F, Liao J, Dai E, Chu T, Cho KS, Jiang J, Yan X, Dai Y, Wang J, Zhang B, Genovese G, Putluri N, Eberlin L, Yang L, Lin C, Kwong LN, Shamsutdinova D, Wani KM, Czerniak BA, Yu W, Zhao J, Guo CC, Hansel D, Pettaway C, Pisters L, Bree K, Navai N, Lee BH, Kamat AM, Sharma P, Corn P, Jiang CY, Shah AY, Alhalabi O, Msaouel P, Siefker-Radtke AO, Logothetis CJ, Campbell MT, Lazar AJ, Gao J, Wang L. A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. Cancer Discov, 2026. e-Pub 2026. PMID: 42126225.
- Wang, R, Luo, M, Liu, Y, Yang, J, Chen, Y, Chen, C, Ma, L, Ding, S, Wengler, J, Zang, Y, Lim, B, Li, W, Yang, L, Lin, C, Diao, L, Han, L. Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer. Advanced Science 13(6), 2026. e-Pub 2026. PMID: 41270088.
- Liu, M, Chatterjee, S, Wu, J, Kashaniasl, Z, Kumar, A, Lin, C, Darabi, R. Ubiquitination-targeted therapies improve BMD iPSC myogenic cell engraftment and dystrophin expression in vivo. Molecular Therapy Methods and Clinical Development 33(3), 2025. e-Pub 2025. PMID: 40677835.
- Chen, MK, Yamaguchi, H, Gao, Y, Xia, W, Chang, J, Hsiao, YC, Shegute, TW, Lin, ZS, Wu, CS, Wang, YH, Litton, J, Ding, Q, Wei, Y, Chu, Y, Meric-Bernstam, F, Piwnica-Worms, H, Arun, BK, Ahnert, JR, Liu, J, Yao, J, Chang, W, Wang, HL, Tapia, C, Albarracin, C, Keyomarsi, K, Wang, SC, Wang, Y, Hortobagyi, GN, Lin, C, Yang, L, Yu, D, Hung, M. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. Journal of Clinical Investigation 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Zhao Z, Hu B, Deng Y, Soeung M, Yao J, Bei L, Zhang Y, Gong P, Huang LA, Jiang Z, Gao J, Peng S, Nguyen TK, Karki M, Lim B, Yee C, Burks JK, Zhang Q, Ma L, Gao J, Tannir NM, Han L, Yu D, Wang L, Curran MA, Gubbiotti MA, Genovese G, Gan B, Li W, Msaouel P, Yang L, Lin C. Sickle cell disease induces chromatin introversion and ferroptosis in CD8(+) T cells to suppress anti-tumor immunity. Immunity 58(6):1484-1501.e11, 2025. e-Pub 2025. PMID: 40359940.
- Wang, R, Chen, C, Liu, Y, Luo, M, Yang, J, Chen, Y, Ma, L, Yang, L, Lin, C, Diao, L, Han, L. The pharmacogenomic and immune landscape of snoRNAs in human cancers. Cancer Letters 605, 2024. e-Pub 2024. PMID: 39426663.
- Luo M, Yang J, Schaffer AA, Chen C, Liu Y, Chen Y, Lin C, Diao L, Zang Y, Lou Y, Salman H, Mills GB, Ruppin E, Han L. Ancestral differences in anti-cancer treatment efficacy and their underlying genomic and molecular alterations. Cancer Discov 15(3):511-529, 2024. e-Pub 2024. PMID: 39601595.
- Gao J, Lin C. Umami (meaty) flavor-containing diet enhance intestinal hyperpermeability. e-Pub 2024.
- Huang LA, Lin C, Yang L. The excessive Phenylalanine facilitates immune suppressive tumor microenvironment of NASH. e-Pub 2024.
- Deng Y, Zhao Z, Sheldon M, Zhao Y, Teng H, Martinez C, Zhang J, Lin C, Sun Y, Yao F, Curran MA, Zhu H, Ma L. LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab 6(9):1756-1774, 2024. e-Pub 2024. PMID: 39147934.
- Xun Z, Zhou H, Shen M, Liu Y, Sun C, Du Y, Jiang Z, Yang L, Zhang Q, Lin C, Hu Q, Ye Y, Han L. Identification of Hypoxia-ALCAM(high) Macrophage- Exhausted T Cell Axis in Tumor Microenvironment Remodeling for Immunotherapy Resistance. Adv Sci (Weinh) 11(33):e2309885, 2024. e-Pub 2024. PMID: 38956900.
- Fu J, Ling J, Li CF, Tsai CL, Yin W, Hou J, Chen P, Cao Y, Kang Y, Sun Y, Xia X, Jiang Z, Furukawa K, Lu Y, Wu M, Huang Q, Yao J, Hawke DH, Pan BF, Zhao J, Huang J, Wang H, Bahassi EIM, Stambrook PJ, Huang P, Fleming JB, Maitra A, Tainer JA, Hung MC, Lin C, Chiao PJ. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Nat Commun 15(1):3149, 2024. e-Pub 2024. PMID: 38605037.
- Ortiz-Vitali JL, Wu J, Xu N, Shieh AW, Niknejad N, Takeuchi M, Paradas C, Lin C, Jafar-Nejad H, Haltiwanger RS, Wang SH, Darabi R. Disease modeling and gene correction of LGMDR21 iPSCs elucidates the role of POGLUT1 in skeletal muscle maintenance, regeneration, and the satellite cell niche. Mol Ther Nucleic Acids 33:683-697, 2023. e-Pub 2023. PMID: 37650119.
- Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
- Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Hawke DH, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung M, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang L. Tumor-Associated Non-Myelinating Schwann Cells-expressed PVT1 Promotes Pancreatic Cancer Kynurenine Pathway and Tumor Immune Exclusion. Science Advance 9(5), 2023. e-Pub 2023. PMID: 36724291.
- Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14(669):eabo1981, 2022. e-Pub 2022. PMID: 36322628.
- Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, Yang WH, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng LB, Hung MC. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem 298(4):101817, 2022. e-Pub 2022. PMID: 35278434.
- Looker HC, Lin C, Nair V, Kretzler M, Mauer M, Najafian B, Nelson RG. Serum Level of Polyubiquitinated PTEN and Loss of Kidney Function in American Indians With Type 2 Diabetes. Am J Kidney Dis 79(4):497-506, 2022. e-Pub 2022. PMID: 34562525.
- Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Profiling of immune features to predict immunotherapy efficacy. Innovation (Camb) 3(1):100194, 2022. e-Pub 2022. PMID: 34977836.
- Li Y, Zhang Y, Hu Q, Egranov SD, Xing Z, Zhang Z, Liang K, Ye Y, Pan Y, Chatterjee SS, Mistretta B, Nguyen TK, Hawke DH, Gunaratne PH, Hung MC, Han L, Yang L, Lin C. Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects. Genome Med 13(1):137, 2021. e-Pub 2021. PMID: 34454586.
- Li Y, Tan Z, Zhang Y, Zhang Z, Hu Q, Liang K, Jun Y, Ye Y, Li YC, Li C, Liao L, Xu J, Xing Z, Pan Y, Chatterjee SS, Nguyen TK, Hsiao H, Egranov SD, Putluri N, Coarfa C, Hawke DH, Gunaratne PH, Tsai KL, Han L, Hung MC, Calin GA, Namour F, Guéant JL, Muntau AC, Blau N, Sutton VR, Schiff M, Feillet F, Zhang S, Lin C, Yang L. A noncoding RNA modulator potentiates phenylalanine metabolism in mice. Science 373(6555):662-673, 2021. e-Pub 2021. PMID: 34353949.
- Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131(8), 2021. e-Pub 2021. PMID: 33855973.
- Thapar R, Wang JL, Hammel M, Ye R, Liang K, Sun C, Hnizda A, Liang S, Maw SS, Lee L, Villarreal H, Forrester I, Fang S, Tsai MS, Blundell TL, Davis AJ, Lin C, Lees-Miller SP, Strick TR, Tainer JA. Mechanism of efficient double-strand break repair by a long non-coding RNA. Nucleic Acids Res 48(19):10953-10972, 2020. e-Pub 2020. PMID: 33045735.
- Zhang Y, Li Y, Hu Q, Xi Y, Xing Z, Zhang Z, Huang L, Wu J, Liang K, Nguyen TK, Egranov SD, Sun C, Zhao Z, Hawke DH, Li J, Sun D, Kim JJ, Zhang P, Cheng J, Farida A, Hung MC, Han L, Darabi R, Lin C, Yang L. The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol 22(11):1332-1345, 2020. e-Pub 2020. PMID: 33106653.
- Zhang Z, Jing J, Ye Y, Chen Z, Jing Y, Li S, Hong W, Ruan H, Liu Y, Hu Q, Wang J, Li W, Lin C, Diao L, Zhou Y, Han L. Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Med 12(1):101, 2020. e-Pub 2020. PMID: 33225964.
- Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 18(1):141, 2019. e-Pub 2019. PMID: 31601234.
- Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu X, Ye Y, Zhang Z, Mills T, Feng J, Liu CJ, Jing J, Cao J, Zhou B, Wang L, Zhou Y, Lin C, Guo AY, Chen X, Diao L, Li W, Chen Z, He X, Mills GB, Blackburn MR, Han L. Comprehensive characterization of circular RNAs in ~?1000 human cancer cell lines. Genome Med 11(1):55, 2019. e-Pub 2019. PMID: 31446897.
- Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer 125(14):2409-2422, 2019. e-Pub 2019. PMID: 31012964.
- Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat Metab 1(4):431-444, 2019. e-Pub 2019. PMID: 31984309.
- Li Y, Hu Q, Li C, Liang K, Xiang Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Ambati CR, Putluri N, Hawke DH, Han L, Hung MC, Danesh FR, Yang L, Lin C. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest 129(3):1129-1151, 2019. e-Pub 2019. PMID: 30741721.
- Hu Q, Li C, Wang S, Li Y, Wen B, Zhang Y, Liang K, Yao J, Ye Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Hawke DH, Marks JR, Han L, Hung MC, Zhang B, Lin C, Yang L. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Cell Res, 2019. e-Pub 2019. PMID: 30631154.
- Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol, 2019. e-Pub 2019. PMID: 31160797.
- Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, Wang Z, Wang Q, Li A, Marks JR, Guo C, Chen Y, Zhou J, Yang L, Lin C, Wang S. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett 430:179-192, 2018. e-Pub 2018. PMID: 29803789.
- Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, Zhou J, Zhou Y, Marks JR, Hawke DH, Hung M, Yang L, Han L, Ying H, Lin C. Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer. Cancer Research, 2018. e-Pub 2018.
- Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo SH, Han L. The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Syst 6(3):314-328.e2, 2018. e-Pub 2018. PMID: 29525205.
- Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 12(127):4498-4515, 2017. e-Pub 2017. PMID: 29130936.
- Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH, Park PK, Diao L, Putkey JA, Yang L, Guo AY, Lin C, Han L. A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Rep 21(7):1968-1981, 2017. e-Pub 2017. PMID: 29141226.
- Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, Wang S, Park PK, Marks JR, Zhou Y, Zhou J, Hung MC, Liang H, Hu Z, Shen H, Hawke DH, Han L, Zhou Y, Lin C, Yang L. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. Nat Cell Biol 19(3):238-251, 2017. e-Pub 2017. PMID: 28218907.
- Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK, Hawke DH, Zhou J, Zhou Y, Zhang S, Liang H, Hung MC, Gallick GE, Han L, Lin C, Yang L. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol 19(2):106-119, 2017. e-Pub 2017. PMID: 28114269.
- Jain AK, Xi Y, McCarthy R, Allton K, Akdemir KC, Patel LR, Aronow B, Lin C, Li W, Yang L, Barton MC. LncPRESS1 Is a p53-Regulated LncRNA that Safeguards Pluripotency by Disrupting SIRT6-Mediated De-acetylation of Histone H3K56. Mol Cell 64(5):967-981, 2016. e-Pub 2016. PMID: 27912097.
- Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung MC, Lin C, Yang L. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol 18(2):213-24, 2016. e-Pub 2016. PMID: 26751287.
- Xing Z, Lin C, Yang L. LncRNA Pulldown Combined with Mass Spectrometry to Identify the Novel LncRNA-Associated Proteins. Methods Mol Biol 1402:1-9, 2016. e-Pub 2016. PMID: 26721478.
- Li N, Zhang Y, Han X, Liang K, Wang J, Feng L, Wang W, Songyang Z, Lin C, Yang L, Yu Y, Chen J. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev 29(2):157-70, 2015. e-Pub 2015. PMID: 25547115.
- Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, Park PK, Qin L, Wei Y, Hawke DH, Hung MC, Lin C, Yang L. LncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. Cell 159(5):1110-25, 2014. e-Pub 2014. PMID: 25416949.
- Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, Zhou H, Li W, Evans CP, Ding S, Rosenfeld MG. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci U S A 111(25):9235-40, 2014. e-Pub 2014. PMID: 24928520.
- Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500(7464):598-602, 2013. e-Pub 2013. PMID: 23945587.
- Yang L, Lin C, Rosenfeld MG. A lincRNA switch for embryonic stem cell fate. Cell Res 21(12):1646-8, 2011. e-Pub 2011. PMID: 22025254.
- Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, Dorrestein PC, Rosenfeld MG. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 147(4):773-88, 2011. e-Pub 2011. PMID: 22078878.
- Carter CL, Lin C, Liu CY, Yang L, Liu ZR. Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter. Oncogene 29(39):5427-36, 2010. e-Pub 2010. PMID: 20676135.
- Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6):1069-83, 2009. e-Pub 2009. PMID: 19962179.
- Yang L, Lin C, Sun SY, Zhao S, Liu ZR. A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis. Oncogene 26(41):6082-92, 2007. e-Pub 2007. PMID: 17384675.
- Yang L, Lin C, Zhao S, Wang H, Liu ZR. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 282(23):16811-9, 2007. e-Pub 2007. PMID: 17412694.
- Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127(1):139-55, 2006. e-Pub 2006. PMID: 17018282.
- Yang L, Lin C, Liu ZR. Signaling to the DEAD box--regulation of DEAD-box p68 RNA helicase by protein phosphorylations. Cell Signal 17(12):1495-504, 2005. e-Pub 2005. PMID: 15927448.
- Lin C, Yang L, Yang JJ, Huang Y, Liu ZR. ATPase/helicase activities of p68 RNA helicase are required for pre-mRNA splicing but not for assembly of the spliceosome. Mol Cell Biol 25(17):7484-93, 2005. e-Pub 2005. PMID: 16107697.
- Yang L, Lin C, Liu ZR. Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Mol Cancer Res 3(6):355-63, 2005. e-Pub 2005. PMID: 15972854.
- Mamidipudi V, Lin C, Seibenhener ML, Wooten MW. Regulation of interleukin receptor-associated kinase (IRAK) phosphorylation and signaling by iota protein kinase C. J Biol Chem 279(6):4161-5, 2004. e-Pub 2004. PMID: 14684752.
- Zang C, Lin C, Li Z. highSpaClone enables copy number alteration inference and tumor subclone analysis for high-resolution spatial transcriptomics. Cell Reports Methods.
Invited Articles
- Lin C, Li Y, Zhang E, Feillet F, Zhang S, Blau N. Importance of the long non-coding RNA (lncRNA) transcript HULC for the regulation of phenylalanine hydroxylase and treatment of phenylketonuria. Mol Genet Metab 135(3):171-178, 2022. e-Pub 2022. PMID: 35101330.
- Wiedemann A, Lin C, Oussalah A, Namour B, É J, Guéant JL, Feillet F. [A long non-coding RNA regulates the activity of phenylalanine hydroxylase, the key enzyme of phenylketonuria]. Med Sci (Paris) 38(1):12-14, 2022. e-Pub 2022. PMID: 35060876.
Review Articles
- Bhadiadra C, Lin C, Yang L. Immune cell lncRNAs reprogram the tumor microenvironment. Trends Cell Biol, 2026. e-Pub 2026. PMID: 42469035.
- Huang LA, Lin C, Yang L. Plumbing mysterious RNAs in "dark genome" for the conquest of human diseases. Mol Ther 31(6):1577-1595, 2023. e-Pub 2023. PMID: 37165619.
- Zong Y, Wang X, Cui B, Xiong X, Wu A, Lin C, Zhang Y. Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease. Mol Ther 31(6):1562-1576, 2023. e-Pub 2023. PMID: 37113055.
- Egranov SD, Hu Q, Lin C, Yang L. LncRNAs as tumor cell intrinsic factors that affect cancer immunotherapy. RNA Biol 17(11):1625-1627, 2020. e-Pub 2020. PMID: 32449433.
- Hu Q, Egranov SD, Lin C, Yang L. Long noncoding RNA loss in immune suppression in cancer. Pharmacol Ther 213:107591, 2020. e-Pub 2020. PMID: 32473960.
- Li Y, Egranov SD, Yang L, Lin C. Molecular mechanisms of long noncoding RNAs-mediated cancer metastasis. Genes Chromosomes Cancer 58(4):200-207, 2019. e-Pub 2019. PMID: 30350428.
- Lin C, Yang L. Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends Cell Biol 28(4):287-301, 2018. e-Pub 2018. PMID: 29274663.
- Xing Z, Park PK, Lin C, Yang L. LncRNA BCAR4 wires up signaling transduction in breast cancer. RNA Biol 12(7):681-9, 2015. e-Pub 2015. PMID: 26016563.
- Li C, Yang L, Lin C. Long noncoding RNAs in Prostate Cancer: Mechanisms and Applications. Molecular & Cellular Oncology 1(3), 2014. e-Pub 2014.
- Lin C, Yang L, Rosenfeld MG. Molecular logic underlying chromosomal translocations, random or non-random?. Adv Cancer Res 113:241-79, 2012. e-Pub 2012. PMID: 22429857.
Editorials
- Shiu PKT, Ilieva M, Holm A, Uchida S, DiStefano JK, Bronisz A, Yang L, Asahi Y, Goel A, Yang L, Nuthanakanti A, Serganov A, Alahari SK, Lin C, Pardini B, Naccarati A, Jin J, Armanios B, Zhong XB, Sideris N, Bayraktar S, Castellano L, Gerber AP, Lin H, Conn SJ, Sleem DMM, Timmons L. The Non-Coding RNA Journal Club: Highlights on Recent Papers-12. Noncoding RNA 9(2), 2023. PMID: 37104010.
Patient Reviews
CV information above last modified September 11, 2026